MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 145086 | Name: Ro 44-3888

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ro 44-3888 is the active principle of sibrafiban. Studies show that oral administration of its prodrug form, Ro 48-3657, resulted in predictable plasma concentrations of Ro 44-3888, achieving steady state after the second dose and demonstrating concentration-dependent inhibition of platelet aggregation and prolongation of bleeding times, suggesting Ro 44-3888 as a promising candidate for further evaluation in patients at risk of arterial thrombosis due to its reproducible absorption and in patients with acute coronary syndrome.

Chemical Structure

Ro 44-3888
Ro 44-3888
CAS#144412-18-0

Theoretical Analysis

MedKoo Cat#: 145086

Name: Ro 44-3888

CAS#: 144412-18-0

Chemical Formula: C18H24N4O5

Exact Mass: 376.1747

Molecular Weight: 376.41

Elemental Analysis: C, 57.44; H, 6.43; N, 14.88; O, 21.25

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
RO-44-3888; RO443888; Ro 44-3888;
IUPAC/Chemical Name
2-((1-((4-carbamimidoylbenzoyl)-L-alanyl)piperidin-4-yl)oxy)acetic acid
InChi Key
BHOGTSLQMNCJHA-NSHDSACASA-N
InChi Code
1S/C18H24N4O5/c1-11(21-17(25)13-4-2-12(3-5-13)16(19)20)18(26)22-8-6-14(7-9-22)27-10-15(23)24/h2-5,11,14H,6-10H2,1H3,(H3,19,20)(H,21,25)(H,23,24)/t11-/m0/s1
SMILES Code
C[C@H](NC(=O)C1=CC=C(C=C1)C(N)=N)C(=O)N2CCC(CC2)OCC(O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 376.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wittke B, Mackie IJ, Machin SJ, Timm U, Zell M, Goggin T. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. Br J Clin Pharmacol. 1999 May;47(5):521-30. doi: 10.1046/j.1365-2125.1999.00931.x. PMID: 10336576; PMCID: PMC2014180. 2: Zell M, Husser C, Hopfgartner G. Column-switching high-performance liquid chromatography combined with ionspray tandem mass spectrometry for the simultaneous determination of the platelet inhibitor Ro 44-3888 and its pro-drug and precursor metabolite in plasma. J Mass Spectrom. 1997 Jan;32(1):23-32. doi: 10.1002/(SICI)1096-9888(199701)32:1<23::AID-JMS449>3.0.CO;2-P. PMID: 9008866. 3: Dooley M, Goa KL. Sibrafiban. Drugs. 1999 Feb;57(2):225-30; discussion 231-2. doi: 10.2165/00003495-199957020-00012. PMID: 10188763. 4: Modi NB, Lin YS, Reynolds T, Shaheen A, Christian BJ. Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles. J Cardiovasc Pharmacol. 1998 Sep;32(3):397-405. doi: 10.1097/00005344-199809000-00010. PMID: 9733353. 5: Wittke B, Ensor H, Chung J, Birnböck H, Lausecker B, Ertel SI, MacKie IJ, Machin SJ. Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. Br J Clin Pharmacol. 2000 Mar;49(3):231-9. doi: 10.1046/j.1365-2125.2000.049003231.x. PMID: 10718778; PMCID: PMC2014917. 6: Refino CJ, Modi NB, Bullens S, Pater C, Lipari MT, Robarge K, Blackburn B, Beresini M, Weller T, Steiner B, Bunting S. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form. Thromb Haemost. 1998 Jan;79(1):169-76. PMID: 9459344. 7: Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadváry P, Müller MH, Knopp D, Levet-Trafit B, Lipari MT, Modi NB, Müller M, Refino CJ, Schmitt M, Schönholzer P, Weiss S, Steiner B. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem. 1996 Aug 2;39(16):3139-47. doi: 10.1021/jm9509298. PMID: 8759635. 8: Thibault G, Tardif P, Lapalme G. Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists. J Pharmacol Exp Ther. 2001 Mar;296(3):690-6. PMID: 11181894. 9: Clement B, Mau S, Deters S, Havemeyer A. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl] amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid). Drug Metab Dispos. 2005 Nov;33(11):1740-7. doi: 10.1124/dmd.105.005249. Epub 2005 Aug 23. PMID: 16118330. 10: Modi NB, Novotny W, Reimann JD, Cannon CP, Braunwauld E. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol. 1999 Jul;39(7):675-84. doi: 10.1177/00912709922008317. PMID: 10392322.

View History

Epelsiban besylate

Epelsiban besylate